Picard Medical, Inc. (PMI)
XASE:PMI
PMI Stock Chart & Stats
$1.82
--
Market closed
$1.82
--
Day’s Range― - ―
52-Week Range$0.92 - $13.68
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.38M
Market Cap
N/A
Enterprise Value$1.48B
Total Cash (Recent Filing)$7.45M
Total Debt (Recent Filing)$5.97M
Price to Earnings (P/E)―
Beta-0.17
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding75,178,535
10 Day Avg. Volume2,124,305
30 Day Avg. Volume2,378,935
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)34.04
Price to Sales (P/S)26.11
P/FCF Ratio-8.23
Enterprise Value/Market Cap10.00T>
Enterprise Value/Revenue299.59
Enterprise Value/Gross Profit7.41K
Enterprise Value/Ebitda-76.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Established Clinical LeadershipA long track record of >2,100 SynCardia implants and documented multi‑year support demonstrates durable clinical validation and real-world device durability. This entrenched clinical experience supports clinician adoption, referral patterns, reimbursement discussions, and a structural market position in total artificial heart therapy.
Next‑generation Fully Implantable Device PipelineAdvancing the Emperor fully implantable, autoregulating artificial heart is a structural product development that could eliminate external drivers and materially expand addressable market and patient quality‑of‑life. Successful translation would strengthen competitive moat and create multi‑year growth runway beyond current SynCardia use.
Balance Sheet Trajectory ImprovingTurning equity positive and reducing debt materially improve solvency versus prior years, providing greater financial flexibility. A healthier capital structure supports continued R&D and commercialization activities and reduces immediate bankruptcy risk, making multi‑quarter execution on strategic programs more feasible.
Bears Say
Persistent And Accelerating Cash BurnSubstantial negative operating cash flow that worsened year‑over‑year signals structural cash consumption from operations. Unless revenue scales rapidly or costs are permanently reduced, the company will remain reliant on external capital, which constrains long‑term strategic options and increases execution risk.
Deep Unprofitability Despite Revenue SpikeA sharp revenue rebound with only marginal gross margin improvement and extreme net losses indicates the business has not yet achieved sustainable unit economics. Structural margin weakness means scaling revenue may not translate to profitability without meaningful cost structure changes or improved gross margins.
Authorized Share Expansion Enables DilutionApproval to dramatically expand authorized shares and permit issuance above 20% under a financing agreement is a structural change enabling significant future equity raises. Given ongoing cash burn, this raises the realistic risk of material dilution, which can impair long‑term shareholder returns and limit upside for existing holders.
Picard Medical, Inc. News
PMI FAQ
What was Picard Medical, Inc.’s price range in the past 12 months?
Picard Medical, Inc. lowest stock price was $0.92 and its highest was $13.68 in the past 12 months.
What is Picard Medical, Inc.’s market cap?
Currently, no data Available
When is Picard Medical, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Picard Medical, Inc.’s earnings last quarter?
Currently, no data Available
Is Picard Medical, Inc. overvalued?
According to Wall Street analysts Picard Medical, Inc.’s price is currently Overvalued.
Does Picard Medical, Inc. pay dividends?
Picard Medical, Inc. does not currently pay dividends.
What is Picard Medical, Inc.’s EPS estimate?
Picard Medical, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Picard Medical, Inc. have?
Picard Medical, Inc. has 75,178,535 shares outstanding.
What happened to Picard Medical, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Picard Medical, Inc.?
Currently, no hedge funds are holding shares in PMI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Picard Medical, Inc.
Picard Medical, Inc., through its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure. The company operates in the USA, Europe, and internationally. The company was incorporated in 2021 and is based in Tucson, Arizona. Picard Medical, Inc. operates as a subsidiary of Hunniwell Picard I, Llc
PMI Company Deck
PMI Earnings Call
Q4 2026
0:00 / 0:00
Technical Analysis
Aethlon Medical
―
Venus Concept
―
Catheter Precision
―
Heart Test Laboratories, Inc.
―
Autonomix Medical, Inc.
―
Ownership Overview
―
Insiders
0.10%
Mutual Funds
0.17% Other Institutional Investors
99.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---